Literature DB >> 22894930

Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.

Ming Wang1, Marianna Halasi, Kasim Kabirov, Aryamitra Banerjee, Jennifer Landolfi, Alexander V Lyubimov, Andrei L Gartel.   

Abstract

Nanoparticle-encapsulated thiazole antibiotic, thiostrepton, has been shown to be an effective agent for inhibiting tumor growth in solid tumor models through the inhibition of proteasomal activity by the induction of apoptosis in cancer cells. Here, we show the efficacy of thiostrepton-micelles in inhibiting tumor growth in a DEN/PB-induced liver cancer model. We also demonstrate an enhanced anticancer effect of the combination treatment of thiostrepton with bortezomib, another proteasome inhibitor in this liver cancer model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22894930      PMCID: PMC3466545          DOI: 10.4161/cc.21290

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  11 in total

1.  Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action.

Authors:  Sebastian Schoof; Gabriele Pradel; Makoah N Aminake; Bernhard Ellinger; Sascha Baumann; Marco Potowski; Yousef Najajreh; Marc Kirschner; Hans-Dieter Arndt
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-26       Impact factor: 15.336

2.  A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.

Authors:  Galina A Gusarova; I-Ching Wang; Michael L Major; Vladimir V Kalinichenko; Timothy Ackerson; Vladimir Petrovic; Robert H Costa
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

3.  Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

Authors:  Lisa J A Crawford; Brian Walker; Huib Ovaa; Dharminder Chauhan; Kenneth C Anderson; Treen C M Morris; Alexandra E Irvine
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

4.  Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.

Authors:  Ming Wang; Andrei L Gartel
Journal:  Cancer Biol Ther       Date:  2012-02-01       Impact factor: 4.742

5.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Authors:  Carol Aghajanian; Steven Soignet; Don S Dizon; Christine S Pien; Julian Adams; Peter J Elliott; Paul Sabbatini; Vincent Miller; Martee L Hensley; Sandra Pezzulli; Christina Canales; Adil Daud; David R Spriggs
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

6.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer.

Authors:  E Wisse; F Jacobs; B Topal; P Frederik; B De Geest
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

7.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Authors:  Christos N Papandreou; Danai D Daliani; Darrell Nix; Hong Yang; Timothy Madden; Xuemei Wang; Christine S Pien; Randall E Millikan; Shi-Ming Tu; Lance Pagliaro; Jeri Kim; Julian Adams; Peter Elliott; Dixie Esseltine; Alexandria Petrusich; Pauline Dieringer; Cherie Perez; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

8.  Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review.

Authors:  Filip Braet; Eddie Wisse
Journal:  Comp Hepatol       Date:  2002-08-23

10.  Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells.

Authors:  Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more
  4 in total

Review 1.  New insights in hepatocellular carcinoma: from bench to bedside.

Authors:  Samuele De Minicis; Marco Marzioni; Antonio Benedetti; Gianluca Svegliati-Baroni
Journal:  Ann Transl Med       Date:  2013-07

2.  FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis.

Authors:  Loka R Penke; Jennifer M Speth; Vijaya L Dommeti; Eric S White; Ingrid L Bergin; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

3.  Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma.

Authors:  Brian Cunniff; Kheng Newick; Kimberly J Nelson; Alexandra N Wozniak; Stacie Beuschel; Bruce Leavitt; Anant Bhave; Kelly Butnor; Andreas Koenig; Edward T Chouchani; Andrew M James; Alexina C Haynes; W Todd Lowther; Michael P Murphy; Arti Shukla; Nicholas H Heintz
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  A Modified Protocol of Diethylnitrosamine Administration in Mice to Model Hepatocellular Carcinoma.

Authors:  Azra Memon; Yuliya Pyao; Yerin Jung; Jung Il Lee; Woon Kyu Lee
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.